Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
BiotechTV - News
00:00
Safety and Patient Selection Shape Development
Markus Warmuth reports a favorable safety profile and explains plans to identify patients with modifiable plaque inflammation for a focused phase two trial.
Play episode from 13:04
Transcript
